share_log

預計虧損大幅減少

EXPECTED SIGNIFICANT REDUCTION IN LOSS

HKEX ·  Jul 25 09:31
Summary by Moomoo AI
微創醫疗科學有限公司於2024年7月25日宣布，預計截至2024年6月30日止六個月的虧損將大幅減少。初步評估顯示，淨虧損約為105百萬至125百萬美元，較去年同期下降約43%至52%。經調整淨虧損預計為65百萬至75百萬美元，同比下降約60%至65%。這一改善主要得益於公司領先產品的商業化推廣、新產品收入增長、全球業務拓展以及海外銷售的快速增長。此外，公司通過實施資源聚焦和成本優化措施、提升運營效率、減少研發和管理費用、強化銷售平台協同，以及出售非核心業務等策略，成功提升盈利能力。微創醫疗表示將繼續推進虧損業務和非核心業務的優化，並致力於實現盈虧平衡。公司將於2024年8月底前發布詳細的中期業績報告。
微創醫疗科學有限公司於2024年7月25日宣布，預計截至2024年6月30日止六個月的虧損將大幅減少。初步評估顯示，淨虧損約為105百萬至125百萬美元，較去年同期下降約43%至52%。經調整淨虧損預計為65百萬至75百萬美元，同比下降約60%至65%。這一改善主要得益於公司領先產品的商業化推廣、新產品收入增長、全球業務拓展以及海外銷售的快速增長。此外，公司通過實施資源聚焦和成本優化措施、提升運營效率、減少研發和管理費用、強化銷售平台協同，以及出售非核心業務等策略，成功提升盈利能力。微創醫疗表示將繼續推進虧損業務和非核心業務的優化，並致力於實現盈虧平衡。公司將於2024年8月底前發布詳細的中期業績報告。
On July 25, 2024, MicroPort Medical Science and Technology Co., Ltd. announced that it is expected to significantly reduce losses for the six months ending on June 30, 2024. Preliminary evaluation shows a net loss of approximately 105 million to 125 million US dollars, a decrease of about 43% to 52% compared to the same period last year. Adjusted net loss is expected to be 65 million to 75 million US dollars, a year-on-year decrease of about 60% to 65%. This improvement is mainly due to the commercial promotion of the company's leading products, the growth of new product revenues, the global expansion of business, and the rapid growth of overseas sales. In addition, the company has successfully improved its profitability by implementing resource focus and cost optimization measures...Show More
On July 25, 2024, MicroPort Medical Science and Technology Co., Ltd. announced that it is expected to significantly reduce losses for the six months ending on June 30, 2024. Preliminary evaluation shows a net loss of approximately 105 million to 125 million US dollars, a decrease of about 43% to 52% compared to the same period last year. Adjusted net loss is expected to be 65 million to 75 million US dollars, a year-on-year decrease of about 60% to 65%. This improvement is mainly due to the commercial promotion of the company's leading products, the growth of new product revenues, the global expansion of business, and the rapid growth of overseas sales. In addition, the company has successfully improved its profitability by implementing resource focus and cost optimization measures, improving operational efficiency, reducing R&D and management expenses, strengthening sales platform collaboration, and selling non-core businesses. MicroPort Medical Science and Technology Co., Ltd. stated that it will continue to optimize loss-making and non-core businesses and strive to achieve a balance between profits and losses. The company will release a detailed mid-term performance report by the end of August 2024.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more